Ingrid Torjesen
The best and worst of acne treatment options
Poor quality trials make assessing effects of non-pharmacological treatments in acne difficult, but based on the evidence, glycolic acid, amino fruit acid, intense pulsed light and diode laser are the most promising.
Medication adherence comes down to cost
Dermatologists should discuss cost and insurance coverage concerns with patients to boost adherence to acne medication, researchers report in JAMA Dermatology.
Biomarkers may predict chronic urticaria resolution
Chronic urticaria is associated with a low resolution rate, but researchers writing in JAMA point to biomarkers that may help predict the likelihood of resolution.
Probiotics may improve pediatric AD symptoms
A daily capsule of a cocktail of probiotics may reduce both the severity symptoms in moderate atopic dermatitis and the need for topical corticosteroids to treat symptom flare ups in children.
Azathioprine and methotrexate safe and effective for atopic dermatitis
A small study finds that the combination of methotrexate and azathioprine is safe and effective as maintenance treatment for patients with moderate-to-severe atopic dermatitis for up to five years.
Considerations for diagnosing eosinophilic fasciitis
A spate of new eosinophilic fasciitis cases led to the development of these considerations now considered standard in making an accurate diagnosis.
Dermatomyositis requires a second-line treatment
Study finds that second-line agents need to be incorporated into treatment for moderate to severe dermatomyositis, which is otherwise very difficult to treat.
Scar treatment dependent on technique
Laser-assisted topical steroid delivery for hypertrophic scars and keloids produces sustainable results, study shows.
Impaired taste and smell may explain poor nutrition in psoriasis patients
Psoriasis has long been linked with poor nutrition, high body mass index and metabolic disorders. New research suggests a reduced sense of taste and smell, caused by inflammation, may explain why.
Genetic variation may explain why biologics help some patients, but fail others
Psoriasis patients carrying a specific gene experience a significantly better early response to ustekinumab, but are less likely to achieve high rates of response to anti-TNFs.